In the biomedical research industry...

In the biomedical research industry, and at Pfizer in particular, we are committed to what we call 'The Three As"--making medicines available, accessible, and affordable.

These "Three As" are closely interconnected. The more therapeutics we make available and the more accessible we make them, the more affordable they become. The whole regularity however, rests on the foundation of availability. And availability is a matter of science, supported from business.

Without a doubt, fresh discoveries will yield many valuable therapeutics from one side of to the other the next decade or likewise But ...